Abstract
Objectives
We examined the efficacy of tolvaptan, an orally effective nonpeptide vasopressin V2 receptor antagonist, in a Japanese clinical study in patients with intractable ascites and/or lower limb edema associated with decompensated liver cirrhosis.
Methods
Tolvaptan was orally administrated at titrated doses of 15, 30, and 60 mg once daily after breakfast for 3 days at each dose to 18 liver cirrhosis patients with persistent ascites and/or lower limb edema despite receiving oral furosemide at 40 mg/day or higher.
Results
Decreased body weight and abdominal circumference and improvement of ascites and edema were observed following tolvaptan administration beginning from 15 mg. Composite ascites/edema improvement rate was 88.2% at individual maximum doses and 64.7, 80.0, and 90.9%, respectively, after 3-day administration at 15, 30, and 60 mg. Changes in body weight after 3-day administration at 15, 30, and 60 mg were −1.6 ± 0.9, −2.6 ± 1.2, and −3.4 ± 2.1 kg (mean ± SD), respectively, and decreases of 1 kg or more were seen from day 2 (24 h after first dosing). Changes in abdominal circumference ranged from −2.8 to −6.0 cm. Cumulative 24-h urine volumes after 3-day administration at 15, 30, and 60 mg were, respectively, 3240.3 ± 1014.5, 3943.3 ± 1060.6, and 4537.4 ± 1621.3 mL/day (mean ± SD). Urine osmolarity was markedly decreased and remained decreased until the end of treatment.
Conclusion
Tolvaptan dose-dependently decreased body weight and abdominal circumference and improved ascites and edema beginning from 15 mg, demonstrating a potent aquaretic effect.
Similar content being viewed by others
References
Guyton AC, Hall JE. Textbook of medical physiology. 10th ed. Philadelphia, PA: WB Saunders Company; 2000. p. 855–6.
Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287(3):860–7.
Doggrell SA. Tolvaptan (Otsuka). Curr Opin Investig Drugs. 2004;5:977–83.
Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol. 2006;290:273–8.
Lieberman FL, Ito S, Reynolds TB. Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a spontaneous reduction in glomerular filtration rate (GFR), a fall in GFR during drug-induced diuresis. J Clin Invest. 1969;48(6):975–81.
Lieberman FL, Denison EK, Reynolds TB. The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis: the “overflow” theory of ascites formation. Ann NY Acad Sci. 1970;170:202–6.
Levy M. Pathophysiology of ascites formation. In: Epstein M, editor. The kidney in liver disease. 2nd ed. New York: Elsevier, 1982. p. 245–80.
Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;8(5):1151–7.
Shoaf SE, Bramer SL, Bricmont P, Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, furosemide or hydrochlorothiazide. J Cardiovasc Phamacol. 2007;50(2):213–22.
Inuyama Symposium Kirokukannkoukai, editors. Proceedings of the 12th Inuyama Symposium: hepatitis A and fulminant hepatitis (in Japanese). Tokyo: Chugai Igakusha; 1982. p. 124.
Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation. 2003;107(21):2690–6.
Gheorghiade M, Konstam MA, Burnet JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials. JAMA. 2007;297(12):1332–43.
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297(12):1319–31.
Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.
Lin SH, Hsu YJ, Chiu JS, Chu SJ, Davids MR, Halperin ML, et al. Osmotic demyelination syndrome: a potentially avoidable disaster. Q J Med. 2003;96:935–47.
Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med. 2007;120(11 Suppl 1):S1–21.
Acknowledgments
The authors are most grateful to their fellow researchers and hospitals for their contribution to data collection.
Author information
Authors and Affiliations
Corresponding author
Additional information
An erratum to this article can be found at http://dx.doi.org/10.1007/s00535-010-0255-z
Rights and permissions
About this article
Cite this article
Okita, K., Sakaida, I., Okada, M. et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose–response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol 45, 979–987 (2010). https://doi.org/10.1007/s00535-010-0240-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00535-010-0240-6